Fundz

201 Therapeutics raises CHF150K from Venture Kick to optimize drug candidates and prepare for future investment.

PRIVATENov 16, 2026

Amount Raised

CHF150,000

Round Type

Seed

BaselBiotechnologyHealth CareTherapeutics

Investors

Venture Kick

Description

201 Therapeutics, a Basel-based biotechnology company, raised CHF150K in funding from Venture Kick. The funds will be used to optimize lead drug candidates and generate preclinical efficacy data. The company is focused on developing targeted small-molecule therapies for liver cancer. Their unique platform tests compounds on patient-derived tumor models for better efficacy.

Quick answer

201 Therapeutics raised CHF150,000 in a Seed round, dated November 16, 2026. Investors: Venture Kick. 201 Therapeutics is based in Basel, Basel City, Switzerland.

How much did 201 Therapeutics raise?
201 Therapeutics raised CHF150,000 in a Seed round on November 16, 2026.
Who invested in 201 Therapeutics?
Venture Kick is named as investors in this round.
What does 201 Therapeutics do?
201 Therapeutics is a biotechnology spin-off from the University of Basel, focusing on developing targeted small-molecule therapies specifically for liver cancer.
Where is 201 Therapeutics based and how big is it?
201 Therapeutics is based in Basel, Basel City, Switzerland.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as 201 Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Seawolf Therapeutics raised $100M (Seed) on November 16, 2026.
  • Yicura BioMed raised an undisclosed amount (Series B) on November 13, 2026.
  • Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
  • Orakl Oncology raised $34M (Series A) on November 12, 2026.
  • VectorY raised $83M on November 11, 2026.
  • Neurosterix raised $105M (Series B) on November 11, 2026.

Who to call at 201 Therapeutics, and when

A new round usually means 201 Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day 201 Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at 201 Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at 201 Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

201 Therapeutics

Location

Basel, Basel City, Switzerland

About

201 Therapeutics is a biotechnology spin-off from the University of Basel, focusing on developing targeted small-molecule therapies specifically for liver cancer. The company employs a unique discovery platform utilizing patient-derived miniature tumor models to test new compounds. Their research has already yielded two proprietary compound series with significant anticancer activity. With plans to optimize lead drug candidates, the company is preparing for future pharmaceutical partnerships.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment 201 Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for 201 Therapeutics's next move

See what Strategic adds

201 Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.